IDiyas

For the Inventor, By the Inventor

Wallingford, CT, United States of America

Dario Doller

USPTO Granted Patents = 10

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 24(Granted Patents)


Company Filing History:

goldMedal10 out of 305 
 
Neurogen Corporation
 patents

Years Active: 2005-2007

Loading Chart...
10 patents (USPTO):Explore Patents
1. 7253168 - Substituted 1-benzyl-4-substituted piperazine analogues (2007-08-07),
2. 7241765 - Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues (2007-07-10),
3. 7202250 - Substituted arylpyrazines (2007-04-10),
4. 7179807 - 5-substituted-2-arylpyrazines (2007-02-20),
5. 7169790 - 5-substituted 2-aryl-4-pyrimidinones (2007-01-30),
6. 7081458 - Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues (2006-07-25),
7. 6995161 - Substituted arylpyrazines (2006-02-07),
8. 6953801 - Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues (2005-10-11),
9. 6943173 - 5-substituted 2-aryl-4-pyrimidinones (2005-09-13),
10. 6887875 - 2,5-diarypyrimidine compounds (2005-05-03),

Title: Dario Doller: A Pioneer in Pharmaceutical Innovations

Introduction

Dario Doller, an accomplished inventor based in Wallingford, CT, has made significant contributions to the field of pharmaceuticals. With an impressive portfolio of ten patents, he has focused on developing compounds that address metabolic, feeding, and sexual disorders in both humans and animals. His work showcases the intersection of innovative chemistry and practical applications in medicine.

Latest Patents

Dario Doller's recent patents delve into the world of melanin concentrating hormone receptor ligands. Notably, he has developed substituted 1-benzyl-4-substituted piperazine analogues, compounds that have the potential to modulate MCH binding to MCH receptors, both in vivo and in vitro. These compounds are particularly useful in treating a variety of disorders, making them a promising avenue for further research. Additionally, he has focused on 1-benzyl-4-aryl piperazine analogues, which also aim to modulate MCH receptor activity and contribute significantly to the treatment of metabolic issues in domesticated animals and livestock.

Career Highlights

As a significant member of Neurogen Corporation, Dario Doller has leveraged his expertise to drive forward pharmaceutical innovations. His collaboration with research teams emphasizes his role in pioneering treatments that can improve the quality of life for pets and livestock alike. His employment at a prominent company underscores the impact of his inventions within the pharmaceutical industry.

Collaborations

Dario Doller's journey is intertwined with notable colleagues, including Taeyoung Yoon and Kevin J Hodgetts. These collaborations foster a synergy that enhances the potential for groundbreaking discoveries, as they work together to research and develop new pharmaceutical compounds.

Conclusion

Dario Doller stands out as a dedicated inventor whose work is reshaping the landscape of pharmaceutical treatments. His patents reflect his commitment to enhancing health outcomes for both humans and animals, showcasing the importance of innovation in the field of medicine. With a solid background and a clear vision for future advancements, Doller's contributions are sure to leave a lasting impact.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…